van Boekel Anniek, Stollenwerck Guido, Ritchie Ewan D, Vogels Sanne
Department of Surgery, Alrijne Hospital, Leiderdorp, The Netherlands.
Department of Surgery, Maastricht UMC, Maastricht, The Netherlands.
Surg J (N Y). 2023 Feb 7;9(1):e39-e43. doi: 10.1055/s-0043-1761270. eCollection 2023 Jan.
Treatment options for xiphodynia are injections with local corticosteroid injections or surgical resection of the xiphoid process. Currently, there is no consensus as to which treatment is the most optimal. The aim of this case series was to compare the safety and efficacy of conservative and surgical treatment for patients with xiphodynia. A retrospective case series was performed. All patients presenting with xiphodynia between 2016 and 2021 were eligible. Demographic data and treatment regimes, including preoperative work-up and surgical technique, were extracted from the electronic patient files. In addition, all patients received a follow-up phone call with a questionnaire. Patient satisfaction was measured using the Numeric Rating Scale. A total of five patients, suffering from xiphodynia for up to 10 years, completed the follow-up questionnaire (median patient age, 57 years; range 51-68 years). Three of these patients initially received conservative treatment with local injections with corticosteroids for at least 6 months. One patient was satisfied with the results and did not opt for surgical treatment. Eventually, four patients were treated surgically by removing the xiphoid process. No postoperative complications were recorded and 100% of the patients who underwent a xiphoidectomy were free of symptoms and satisfied with the results. Symptoms related to xiphodynia can be relieved using conservative or surgical treatment, where the latter seems to be a safe and effective solution.
剑突痛的治疗选择包括局部注射皮质类固醇或手术切除剑突。目前，对于哪种治疗方法最为理想尚无共识。 本病例系列的目的是比较保守治疗和手术治疗对剑突痛患者的安全性和有效性。 进行了一项回顾性病例系列研究。所有在2016年至2021年间出现剑突痛的患者均符合条件。从电子病历中提取人口统计学数据和治疗方案，包括术前检查和手术技术。此外，所有患者都接到了一个随访电话并收到一份问卷。使用数字评分量表来衡量患者满意度。 共有5名患有剑突痛长达10年的患者完成了随访问卷（患者年龄中位数为57岁；范围为51 - 68岁）。其中3名患者最初接受了局部注射皮质类固醇的保守治疗，为期至少6个月。1名患者对结果满意，未选择手术治疗。最终，4名患者通过切除剑突接受了手术治疗。未记录到术后并发症，接受剑突切除术的患者中有100%症状消失且对结果满意。 与剑突痛相关的症状可以通过保守治疗或手术治疗得到缓解，其中手术治疗似乎是一种安全有效的解决方案。
